Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Regeneron Pharmaceuticals Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data reveals several key trends in the company's performance from 2020 through 2024.

Net Operating Profit After Taxes (NOPAT)
NOPAT exhibited significant volatility over the observed period. It increased sharply from approximately $3.7 billion in 2020 to nearly $7.8 billion in 2021, more than doubling within a year. However, this peak was followed by a pronounced decline in 2022 to about $3.5 billion and continued downward to roughly $2.8 billion in 2023. A moderate recovery took place in 2024 with NOPAT rising to approximately $3.4 billion. Despite fluctuations, the 2024 NOPAT remains below the 2021 peak, indicating variability in operational profitability.
Cost of Capital
The cost of capital showed a relatively stable, slightly upward trend across the five years. It increased modestly from 5.57% in 2020 to 5.61% in 2021, then continued incremental rises, peaking at 5.69% in 2023 before a slight decrease to 5.67% in 2024. This stability suggests consistent financing costs with minor variations.
Invested Capital
Invested capital increased steadily throughout the period, rising from $8.4 billion in 2020 to $12.7 billion in 2024. The most notable jumps occurred between 2020 and 2021 and again from 2022 to 2024, indicating ongoing investment in assets or resources tied to the company’s operations. This upward trend reflects growth in capital employed in the business over the five years.
Economic Profit
Economic profit mirrored the general pattern observed in NOPAT with notable fluctuations. Starting at approximately $3.2 billion in 2020, it surged to $7.2 billion in 2021 before declining sharply to about $2.8 billion in 2022 and further dropping to $2.1 billion in 2023. There was a modest rebound in 2024 to around $2.7 billion. Despite these oscillations, economic profit remained positive throughout, implying that the company consistently generated returns above its cost of capital, albeit with variability in value creation.

Overall, the data indicate a period of marked growth and contraction in profitability measures, paired with a steady rise in invested capital and stable financing costs. The fluctuations in operating profit and economic profit suggest external or internal factors influencing performance, while the consistent increase in invested capital may signal strategic investments or expansion efforts aiming for long-term growth despite short-term profit variability.


Net Operating Profit after Taxes (NOPAT)

Regeneron Pharmaceuticals Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
(Gain) loss on marketable securities
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net income.

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net income.

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Income Trend
The net income exhibited significant volatility over the five-year period. It increased markedly from approximately $3.51 billion in 2020 to a peak of $8.08 billion in 2021. However, in the subsequent years, net income declined sharply to about $4.34 billion in 2022 and further declined to $3.95 billion in 2023. There was a moderate recovery observed in 2024, with net income increasing to roughly $4.41 billion.
Net Operating Profit After Taxes (NOPAT) Trend
The NOPAT also showed a similar pattern of fluctuation. Starting at approximately $3.70 billion in 2020, it rose significantly to around $7.82 billion in 2021. After this peak, NOPAT experienced a marked decrease to about $3.55 billion in 2022, continuing its downward trend to approximately $2.82 billion in 2023. A slight improvement is noted in 2024, where NOPAT increased to nearly $3.37 billion.
Comparative Analysis Between Net Income and NOPAT
Both net income and NOPAT followed parallel trajectories, with substantial growth in 2021 followed by pronounced declines in 2022 and 2023, and moderate recovery in 2024. Notably, the decline in NOPAT after 2021 was somewhat steeper than the decline in net income, particularly between 2022 and 2023. Despite the fluctuations, net income consistently remained slightly lower than NOPAT throughout the period, indicating possible differences in non-operating income, expenses, or tax effects.
General Insights
The data reveals a peak in profitability metrics in 2021, suggestive of exceptional performance or favorable conditions during that year. The subsequent deterioration through 2022 and 2023 may imply operational challenges, increased expenses, or adverse market conditions impacting operational efficiency and profitability. The modest rebound in 2024 suggests some recovery, though neither net income nor NOPAT returned to the peak levels observed in 2021.

Cash Operating Taxes

Regeneron Pharmaceuticals Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax expense
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data reveals notable fluctuations in tax-related expenses over the five-year period under review. Income tax expense and cash operating taxes show varying trends that indicate changes in the company’s profitability, tax strategies, or regulatory environment impacts.

Income Tax Expense
This item increased substantially from 297,200 thousand US dollars in 2020 to a peak of 1,250,500 thousand US dollars in 2021, representing a more than fourfold increase. The subsequent years show a marked decrease to 520,400 thousand US dollars in 2022 and further declines to 245,700 thousand US dollars in 2023. In 2024, there was a modest recovery to 367,300 thousand US dollars. These changes suggest significant variations in taxable income or effective tax rates year over year.
Cash Operating Taxes
Cash operating taxes exhibit a different pattern. Starting at 212,370 thousand US dollars in 2020, these taxes surge to 1,400,760 thousand US dollars in 2021, exceeding the income tax expense increase, which may indicate timing differences or adjustments in tax payments versus accruals. Unlike income tax expense, cash operating taxes peaked in 2022 at 1,246,398 thousand US dollars, only slightly decreasing thereafter to 995,682 thousand US dollars in 2023 and stabilizing around 989,515 thousand US dollars in 2024. This suggests that cash payments for taxes remained relatively high and steady after the initial spike in 2021.

Overall, the data points to a significant tax-related financial impact in 2021 followed by a normalization trend in subsequent years, though cash operating taxes remained at elevated levels compared to 2020. The divergence between income tax expense and cash operating taxes in later years could reflect changes in deferred tax assets or liabilities, timing differences, or tax planning strategies.


Invested Capital

Regeneron Pharmaceuticals Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Finance lease liabilities, current portion
Long-term debt
Finance lease liabilities, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity
Construction in progress6
Marketable securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of marketable securities.


Total Reported Debt & Leases
The total reported debt and leases remained relatively stable from 2020 to 2023, fluctuating slightly around the 2.76 to 2.79 billion US dollars range. In 2024, there was a noticeable increase to approximately 2.94 billion, indicating a rise in the company's leverage or financing obligations during that year.
Stockholders’ Equity
Stockholders’ equity showed a strong and consistent upward trend across the entire period. Starting at about 11.03 billion in 2020, it increased significantly each year, reaching nearly 29.35 billion by the end of 2024. This growth suggests robust retained earnings and possibly additional equity financing, reflecting an overall strengthening in the company’s net worth and financial position.
Invested Capital
Invested capital experienced growth from 8.42 billion in 2020 to a peak of approximately 12.29 billion in 2022. However, a decline followed in 2023, dropping to about 12.00 billion, before rising again to roughly 12.65 billion in 2024. This pattern indicates a moderate fluctuation in the capital deployed within the business, which could be related to changes in assets or operational investments during the period.

Cost of Capital

Regeneron Pharmaceuticals Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Long-term debt and finance lease liabilities3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Long-term debt and finance lease liabilities. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Regeneron Pharmaceuticals Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit Trend
The economic profit demonstrates significant fluctuations over the five-year period. Starting at approximately 3.23 billion USD in 2020, it more than doubled to reach a peak of about 7.21 billion USD in 2021. However, in the subsequent years, economic profit declined substantially to around 2.85 billion USD in 2022 and continued decreasing to approximately 2.14 billion USD in 2023. There is a slight recovery in 2024, with economic profit increasing to roughly 2.66 billion USD. Overall, the economic profit exhibits volatility, with a pronounced peak in 2021 followed by a notable downturn.
Invested Capital Analysis
Invested capital has shown a steady upward trend throughout the five-year period. Beginning at 8.42 billion USD in 2020, it consistently increased each year, reaching 10.79 billion in 2021, 12.29 billion in 2022, experiencing a slight decrease to about 12.00 billion USD in 2023, then rising again to 12.65 billion USD in 2024. Despite the minor dip in 2023, the overall pattern indicates ongoing capital investment expansion.
Economic Spread Ratio Insights
The economic spread ratio reflects the company’s ability to generate returns relative to invested capital. This ratio started at 38.38% in 2020 and saw a substantial increase to 66.88% in 2021, correlating with the peak in economic profit during the same year. However, the ratio sharply declined to 23.19% in 2022 and then decreased further to 17.84% in 2023. In 2024, there is a modest improvement, with the ratio rising to 21%. The trend suggests initially strong returns that diminished considerably after 2021, with some signs of stabilization or recovery in the most recent year.
Overall Observations
The financial data indicates an initial period of strong economic performance in 2021, characterized by peak economic profit and economic spread ratio, alongside a rising invested capital base. Subsequent years show a notable decline in profitability measures despite continued growth in invested capital, signaling potential challenges in maintaining return levels on increased capital deployment. The slight rebound in 2024 could point toward efforts to enhance economic returns, but overall economic profit and spread remain below their peak values.

Economic Profit Margin

Regeneron Pharmaceuticals Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The analysis of the financial data over the five-year period reveals several notable trends in economic profit, adjusted revenues, and economic profit margin.

Economic Profit
The economic profit demonstrated a significant rise from 3,233,170 thousand US dollars in 2020 to a peak of 7,214,365 thousand US dollars in 2021. However, following this peak, there was a marked decline over the next two years, dropping to 2,849,427 thousand in 2022 and further decreasing to 2,140,031 thousand in 2023. In 2024, there is a slight recovery, with economic profit increasing to 2,657,277 thousand.
Adjusted Revenues
Adjusted revenues showed strong growth from 8,645,200 thousand US dollars in 2020 to a high of 15,951,500 thousand in 2021, nearly doubling within one year. After 2021, revenues decreased to 12,205,300 thousand in 2022 but then rebounded in the following years, reaching 13,155,100 thousand in 2023 and further improving to 14,429,800 thousand in 2024.
Economic Profit Margin
The economic profit margin experienced a similar volatility pattern as economic profit. The margin increased from 37.4% in 2020 to its highest point of 45.23% in 2021, indicating enhanced profitability relative to revenue. Subsequently, the margin declined sharply in 2022 to 23.35%, and continued to decrease to 16.27% in 2023. A modest improvement to 18.42% is observed in 2024, suggesting some recovery in efficiency or profitability.

Overall, the data indicates that the company achieved substantial growth in both economic profit and revenues at the beginning of the period, with 2021 as a standout year. However, this was followed by a notable downturn through 2022 and 2023, with some signs of stabilization and recovery in 2024. The decline in economic profit margin in the later years highlights challenges in maintaining profitability despite recovering revenues. This pattern may warrant further investigation into cost management, pricing strategies, or market conditions affecting profitability post-2021.